Quick Answer
Nurix Therapeutics, Inc. reported Stockholders Equity of $538.75 million for fiscal year 2025.
Nurix Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $538.75M | +2.2% |
| 2024 | $526.99M | +162.8% |
| 2023 | $200.49M | -34.0% |
| 2022 | $303.70M | -11.3% |
| 2021 | $342.30M | +17.9% |
| 2020 | $290.27M | +602.9% |
| 2019 | -$57.71M | -56.6% |
| 2018 | -$36.85M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| August 31, 2025 | $372.25M | -1.2% | -16.8% |
| May 31, 2025 | $447.60M | +20.7% | -6.9% |
| February 28, 2025 | $480.92M | +185.0% | -8.7% |
| November 30, 2024 | $526.99M | +162.8% | +39.8% |
| August 31, 2024 | $376.86M | +61.2% | +1.7% |
| May 31, 2024 | $370.69M | +42.6% | +119.7% |
| February 29, 2024 | $168.75M | -38.4% | -15.8% |
| November 30, 2023 | $200.49M | -34.0% | -14.3% |
- Nurix Therapeutics, Inc. showed an increase of +2.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Nurix Therapeutics, Inc.’s stockholders equity has grown by 1562.1% (from -$36.85 million to $538.75 million).
- The most recent figure is from Nurix Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on January 28, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: